- Home
- FYBR vs EXEL Comparison
FYBR vs EXEL Comparison
Compare FYBR & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FYBR
- EXEL
- Stock Information
- Founded
- FYBR 1935
- EXEL 1994
- Country
- FYBR United States
- EXEL United States
- Employees
- FYBR N/A
- EXEL N/A
- Industry
- FYBR Telecommunications Equipment
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FYBR Consumer Discretionary
- EXEL Health Care
- Exchange
- FYBR Nasdaq
- EXEL Nasdaq
- Market Cap
- FYBR 9.2B
- EXEL 9.8B
- IPO Year
- FYBR N/A
- EXEL 2000
- Fundamental
- Price
- FYBR $36.28
- EXEL $43.64
- Analyst Decision
- FYBR Buy
- EXEL Buy
- Analyst Count
- FYBR 9
- EXEL 18
- Target Price
- FYBR $35.33
- EXEL $38.76
- AVG Volume (30 Days)
- FYBR 4.1M
- EXEL 3.9M
- Earning Date
- FYBR 04-29-2025
- EXEL 05-13-2025
- Dividend Yield
- FYBR N/A
- EXEL N/A
- EPS Growth
- FYBR N/A
- EXEL 237.58
- EPS
- FYBR N/A
- EXEL 2.20
- Revenue
- FYBR $5,986,000,000.00
- EXEL $2,298,922,000.00
- Revenue This Year
- FYBR $4.58
- EXEL $10.39
- Revenue Next Year
- FYBR $3.32
- EXEL $10.74
- P/E Ratio
- FYBR N/A
- EXEL $19.53
- Revenue Growth
- FYBR 3.69
- EXEL 24.49
- 52 Week Low
- FYBR $24.43
- EXEL $20.40
- 52 Week High
- FYBR $39.21
- EXEL $48.85
- Technical
- Relative Strength Index (RSI)
- FYBR 39.24
- EXEL 59.93
- Support Level
- FYBR $36.36
- EXEL $42.21
- Resistance Level
- FYBR $36.75
- EXEL $43.75
- Average True Range (ATR)
- FYBR 0.19
- EXEL 1.60
- MACD
- FYBR -0.06
- EXEL -0.09
- Stochastic Oscillator
- FYBR 11.50
- EXEL 53.96
About FYBR Frontier Communications Parent Inc.
Frontier Communications Parent Inc is a communications and technology provider offering broadband services. The company provides voice services, including data-based voice over Internet protocol (VoIP) and unified communications as a service (UCaaS), as well as long-distance and voice messaging services, to consumer and business customers in all its markets.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.